| Literature DB >> 25349174 |
Emma M Haapaniemi1, Meri Kaustio2, Hanna L M Rajala3, Arjan J van Adrichem2, Leena Kainulainen4, Virpi Glumoff5, Rainer Doffinger6, Heikki Kuusanmäki2, Tarja Heiskanen-Kosma7, Luca Trotta2, Samuel Chiang8, Petri Kulmala9, Samuli Eldfors2, Riku Katainen10, Sanna Siitonen11, Marja-Liisa Karjalainen-Lindsberg11, Panu E Kovanen12, Timo Otonkoski13, Kimmo Porkka3, Kaarina Heiskanen14, Arno Hänninen15, Yenan T Bryceson8, Raija Uusitalo-Seppälä16, Janna Saarela2, Mikko Seppänen17, Satu Mustjoki3, Juha Kere18.
Abstract
The signal transducer and activator of transcription (STAT) family of transcription factors orchestrate hematopoietic cell differentiation. Recently, mutations in STAT1, STAT5B, and STAT3 have been linked to development of immunodysregulation polyendocrinopathy enteropathy X-linked-like syndrome. Here, we immunologically characterized 3 patients with de novo activating mutations in the DNA binding or dimerization domains of STAT3 (p.K392R, p.M394T, and p.K658N, respectively). The patients displayed multiorgan autoimmunity, lymphoproliferation, and delayed-onset mycobacterial disease. Immunologically, we noted hypogammaglobulinemia with terminal B-cell maturation arrest, dendritic cell deficiency, peripheral eosinopenia, increased double-negative (CD4(-)CD8(-)) T cells, and decreased natural killer, T helper 17, and regulatory T-cell numbers. Notably, the patient harboring the K392R mutation developed T-cell large granular lymphocytic leukemia at age 14 years. Our results broaden the spectrum of phenotypes caused by activating STAT3 mutations, highlight the role of STAT3 in the development and differentiation of multiple immune cell lineages, and strengthen the link between the STAT family of transcription factors and autoimmunity.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25349174 PMCID: PMC4304109 DOI: 10.1182/blood-2014-04-570101
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113